Capital and Industry Converge, Quality Drives Innovation: 2024 Changping Healthcare Innovative Financial Investment Forum (2024CHIF) Unveils Full Agenda
Active government policy support and the vigorous participation of financial capital have injected new momentum into China’s pharmaceutical and healthcare industry. The global surge in investment in biotechnology and innovative drugs has driven industrial innovation and enhanced efficiency. In China, the maturation of capital markets has attracted private equity, venture capital, and other financial activities, providing the funding and confidence necessary for the sustained prosperity of the pharmaceutical and healthcare sector. This ensures long-term, stable growth and points to a vibrant and innovative future for the industry.
On November 22, 2024, the 2024 Changping Healthcare Innovative Financial Investment Forum (CHIF) was held at the Jiuhua Resort in Changping District, Beijing. Co-hosted by the People’s Government of Changping District, Beijing State-owned Capital Operation and Management Co., Ltd., and jointly organized by the Administrative Committee of Future Science City (Life Science Park), the Administrative Committee of Zhongguancun Science Park Changping Park, the Development and Reform Commission of Changping District, Beijing Changping Science and Technology Park Development Group Co., Ltd., Beijing Changke Jin Investment Co., Ltd., and Chongqing Dongmaicheng Technology Co., Ltd. (VCBeat VB100), the forum centered on the core theme of “Synergizing Industry and Finance to Create a Quality Future.” Leveraging Changping District’s unique industrial and financial resource advantages, the event brought together government officials, academicians, scientists, clinical experts, top-tier investors, and corporate leaders from across the healthcare ecosystem. Attendees engaged in discussions and knowledge sharing on cutting-edge technologies, innovative applications, economic trends, and policy directions in key sectors such as biopharmaceuticals and medical devices.
Industry Leaders Convene to Explore New Drivers for High-Quality Industrial Development
This edition of the CHIF Forum will invite more than 30 distinguished industry leaders, including government officials, academicians from the Chinese Academy of Sciences and the Chinese Academy of Engineering, economists, chief analysts from stock exchanges, representatives from listed companies, innovative enterprises, and renowned financial investment institutions. Together, they will discuss and share insights on cutting-edge technologies, innovative applications, economic trends, and policy directions in key sectors such as biopharmaceuticals and medical devices.
Multidimensional Ecosystem: Uniting New Industry Synergy to Drive Quality-Led Innovation
As a high-quality forum featuring the dual platforms of “Pharmaceutical & Healthcare + Financial Investment Experience Sharing Platform” and “Pharmaceutical & Healthcare Industry Linkage and Innovation Ecosystem Cooperation Platform,” it brings togetherAstraZeneca, BeiGene, MGI Tech, XtalPi, Sanbo Brain Hospital, Siemens Healthineers, Chengyi Biopharma, Guoke Rongzhi Bio, Huixin Yigu, Keshihua Bio, and other enterprises; FreeS Fund, Jianyi Capital, Legend Capital, Medtronic China Medical Fund, Tsinghua Industrial Research Institute Global Health Industry Innovation Center, Shuimu Ventures, Shunxi Private Equity Fund, Xianfeng Qiyun, and China Securities Co., Ltd.and other institutions, bringing abundant information resources and collaboration opportunities, promoting cross-disciplinary and cross-industry exchanges and cooperation, and jointly building a multidimensional collaborative ecosystem for the pharmaceutical and health industries.
Convergence of Wisdom, Inspiring InnovationQualityEmpowering Minds to Spark New Ideas
From frontier insights in biotechnology and in-depth analyses of healthcare policies, to outlooks on IPO trends in the pharmaceutical and health sectors, discussions on “building ships to sail overseas” strategies against the backdrop of international cooperation, and two major roundtable forums themed “Source Innovation and Breakthroughs” and “Chain Expansion Innovation and Ecosystem,” every segment closely aligns with industry hotspots and cutting-edge trends. The forum aims to spark dynamic interactions between innovative thinking and financial capital, guiding the industry toward a new stage of high-quality development. Below are the hotspot topics of this year’s forum:
● How is synthetic biology breaking through traditional limitations in new drug development? How will the automation and intelligence of synthetic chemistry impact the preparation of small-molecule drugs?
● How has value-based healthcare become the core objective of healthcare reform? How can payment system reform be integrated with value-based healthcare?
● How will IPO trends in the pharmaceutical and healthcare sector shape the capital markets? How can pharmaceutical and healthcare companies stand out amidst the IPO surge?
● How to make optimal pathway choices among the essential options for global expansion? Where lie the new growth poles for medical device companies going global? Why has the wave of innovative drugs going global emerged at this juncture?
Why is source innovation in medical technology particularly crucial? How will new quality productive forces, a key industrial focus—such as synthetic biology, brain-computer interfaces, cell and gene therapy, and AI-driven drug discovery—lead the next wave of medical revolution?
● How can deep integration and expansion be promoted across the upstream and downstream segments of the industrial chain? How can enterprises build an effective innovation ecosystem to achieve optimization, upgrading, and expansion of the industrial chain?
